RATIONALE: Benzodiazepines are associated with mortality and poor outcomes among patients with chronic obstructive pulmonary disease (COPD), but use of benzodiazepines for dyspnea among patients with end-stage disease may confound this relationship. OBJECTIVES: Assess the mortality risks of long-term benzodiazepine exposure among patients with COPD and comorbid post-traumatic stress disorder (PTSD), patients with chronic nonrespiratory indications for benzodiazepines. METHODS: We identified all patients with COPD and PTSD within the Veteran's Health Administration between 2010 and 2012. We calculated propensity scores for benzodiazepine use and compared overall and cause-specific mortality of patients with long-term (≥90 d) benzodiazepine use relative to matched patients without use. Secondary analyses assessed propensity-adjusted survival by characteristics of benzodiazepine exposure. RESULTS: Among 44,555 eligible patients with COPD and PTSD, 23.6% received benzodiazepines long term. In the matched sample of 19,552 patients, we observed no mortality difference (hazard ratio [HR] for long-term use, 1.06; 95% confidence interval [CI], 0.95-1.18) but greater risk of death by suicide among those with long-term use (HR, 2.33; 95% CI, 1.14-4.79). Among matched and unmatched patients, short-term benzodiazepine use, but not long-term use, was associated with increased mortality (short-term: HR, 1.16; 95% CI, 1.05-1.28; long-term: HR, 1.03; 95% CI, 0.94-1.13). CONCLUSIONS: Risks for respiratory compromise related to long-term benzodiazepine use in COPD may be less than previously estimated, but short-term use of benzodiazepines could still pose a mortality risk. Suicide associated with benzodiazepine use in this population warrants further investigation.
RATIONALE: Benzodiazepines are associated with mortality and poor outcomes among patients with chronic obstructive pulmonary disease (COPD), but use of benzodiazepines for dyspnea among patients with end-stage disease may confound this relationship. OBJECTIVES: Assess the mortality risks of long-term benzodiazepine exposure among patients with COPD and comorbid post-traumatic stress disorder (PTSD), patients with chronic nonrespiratory indications for benzodiazepines. METHODS: We identified all patients with COPD and PTSD within the Veteran's Health Administration between 2010 and 2012. We calculated propensity scores for benzodiazepine use and compared overall and cause-specific mortality of patients with long-term (≥90 d) benzodiazepine use relative to matched patients without use. Secondary analyses assessed propensity-adjusted survival by characteristics of benzodiazepine exposure. RESULTS: Among 44,555 eligible patients with COPD and PTSD, 23.6% received benzodiazepines long term. In the matched sample of 19,552 patients, we observed no mortality difference (hazard ratio [HR] for long-term use, 1.06; 95% confidence interval [CI], 0.95-1.18) but greater risk of death by suicide among those with long-term use (HR, 2.33; 95% CI, 1.14-4.79). Among matched and unmatched patients, short-term benzodiazepine use, but not long-term use, was associated with increased mortality (short-term: HR, 1.16; 95% CI, 1.05-1.28; long-term: HR, 1.03; 95% CI, 0.94-1.13). CONCLUSIONS: Risks for respiratory compromise related to long-term benzodiazepine use in COPD may be less than previously estimated, but short-term use of benzodiazepines could still pose a mortality risk. Suicide associated with benzodiazepine use in this population warrants further investigation.
Authors: Risë B Goldstein; Sharon M Smith; S Patricia Chou; Tulshi D Saha; Jeesun Jung; Haitao Zhang; Roger P Pickering; W June Ruan; Boji Huang; Bridget F Grant Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2016-04-22 Impact factor: 4.328
Authors: Rohit Budhiraja; Sairam Parthasarathy; Pooja Budhiraja; Michael P Habib; Christopher Wendel; Stuart F Quan Journal: Sleep Date: 2012-03-01 Impact factor: 5.849
Authors: Ranak B Trivedi; Edward P Post; Haili Sun; Andrew Pomerantz; Andrew J Saxon; John D Piette; Charles Maynard; Bruce Arnow; Idamay Curtis; Stephan D Fihn; Karin Nelson Journal: Am J Public Health Date: 2015-10-16 Impact factor: 9.308
Authors: Nicholas T Vozoris; Hadas D Fischer; Xuesong Wang; Geoffrey M Anderson; Chaim M Bell; Andrea S Gershon; Anne L Stephenson; Sudeep S Gill; Paula A Rochon Journal: Drugs Aging Date: 2013-03 Impact factor: 3.923
Authors: Sara Fleehart; Vincent S Fan; Huong Q Nguyen; Jungeun Lee; Ruth Kohen; Jerald R Herting; Gustavo Matute-Bello; Sandra G Adams; Genevieve Pagalilauan; Soo Borson Journal: Int J Chron Obstruct Pulmon Dis Date: 2014-12-04
Authors: Lucas M Donovan; Carol A Malte; Laura J Spece; Matthew F Griffith; Laura C Feemster; Steven B Zeliadt; David H Au; Eric J Hawkins Journal: Ann Am Thorac Soc Date: 2019-09
Authors: Jeremy E Orr; Christopher N Schmickl; Bradley A Edwards; Pamela N DeYoung; Rebbecca Brena; Xiaoying S Sun; Sonia Jain; Atul Malhotra; Robert L Owens Journal: Physiol Rep Date: 2020-02